Ovarian cancer is the 2nd most common gynecologic malignancy, and the 6th leading cause of cancer-related deaths among women in the US.1,2
annual diagnosed
cases in the US2
5-year survival rate3
annual US deaths2
of patients pass away from
late-stage disease4
Ovarian cancer is diagnosed in stages III to IV in ~75% of cases5
Nonspecific symptoms common in ovarian cancer can be misattributed to other conditions or health issues.6
Pain
Fullness or abdominal girth
Urinary symptoms
Gastrointestinal symptoms
Ovarian cancer with a treatment-free interval of <6 months since the last
line of treatment with platinum chemotherapy7
~85% of patients experience recurrence and become platinum resistant7
Women diagnosed with ovarian cancer typically undergo surgery and platinum-based chemotherapy in frontline treatment.8
The realities of PROC are challenging
Despite recent advancements, results with standard of care leave women with a challenging journey.11
become resistant to platinum chemotherapy7
median progression-free survival with current options12
median overall survival with current options12
are eligible for FDA-approved biomarker therapy11
Management is focused on balancing tolerability, quality of life, and
outcomes for each individual patient11,12
There have been 2 therapies approved by the FDA for platinum-resistant ovarian cancer in the last decade. Treatment outcomes are typically poor, with disease progression in ~3-4 months with single-agent chemotherapy.11-13
Platinum-resistant ovarian cancer treatment options include single-agent chemotherapy ± bevacizumab, biomarker-targeted therapies, and investigational therapies. However, the side effects and modest efficacy of current therapies can make treatment decisions challenging.8,11,14
New studies are elucidating previously unknown resistance mechanisms in ovarian cancer. Ongoing research and innovative pipeline candidates may lead to new treatments and improve outcomes in the management of platinum-resistant ovarian cancer.15
1. Arter ZL, Desmond D, Berenberg JL, Killeen JL, Bunch K, Merritt MA. Br J Cancer. 2024;130(1):108-113. 2. National Cancer Institute. Cancer Stat Facts: Common Cancer Sites. Surveillance, Epidemiology, and End Results Program. 2024. Accessed December 11, 2024. https://seer.cancer.gov/statfacts/html/common.html 3. National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. Surveillance, Epidemiology, and End Results Program. 2024. Accessed December 11, 2024. https://seer.cancer.gov/statfacts/html/ovary.html 4. Lheureux S, Braunstein M, Oza AM. CA Cancer J Clin. 2019;69(4):280-304. 5. Ghirardi V, Fagotti A, Ansaloni L, et al. Cancers (Basel). 2023;15(2):407. 6. Chan JK, Tian C, Kesterson JP, et al. Obstet Gynecol. 2022;139(2):157-162. 7. St Laurent J, Liu JF. J Clin Oncol. 2024;42(2):127-133. 8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. 2024. July 19, 2024. Accessed December 11, 2024. https://www.nccn.org/patients/guidelines/content/PDF/ovarian-patient.pdf 9. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. J Natl Compr Canc Netw. 2021;19(2):191-226. 10. Liu JF. J Natl Compr Canc Netw. 2023;21(5.5):1-4. 11. Matulonis UA, Lorusso D, Oaknin A, et al. J Clin Oncol. 2023;41(13):2436-2445. 12. Richardson DL, Eskander RN, O’Malley DM. JAMA Oncol. 2023;9(6):851-859. 13. FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA. March 22, 2024. Accessed December 11, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian 14. Osman MA, Elkady MS, Nasr KE. Clin Med Insights Oncol. 2016;10:35-41. 15. Colombo N, Van Gorp T, Matulonis UA, et al. J Clin Oncol. 2023;41(30):4779-4789.
